Guardant Health (GH) Stock Price
Guardant Health Price
Guardant Health (GH) Stock | ISIN US40131M1099 | WKN A2N5RY. The current Guardant Health stock price is 131.64 USD (2026). Revenue is 1.27 B USD. Net income is -323.05 M USD. The P/E ratio is -50.02. Market capitalization is 16.96 B USD. Guardant Health operates in the Health sector.
Guardant Health stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Guardant Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Guardant Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Guardant Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Guardant Health Price |
|---|
Guardant Health Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Guardant Health Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Guardant Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Guardant Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Guardant Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Guardant Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Guardant Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Guardant Health stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Guardant Health Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Guardant Health business model & stock analysis
Guardant Health SWOT Analysis
Strengths
1. Proprietary liquid biopsy technology: Guardant Health Inc has developed advanced liquid biopsy technology, which allows for non-invasive genetic testing and enables early detection of cancer and other diseases.
2. Strong brand reputation: Guardant Health has established a strong brand reputation within the healthcare industry for its innovative and reliable diagnostic tests.
3. Strategic partnerships: The company has formed strategic partnerships with leading pharmaceutical companies and research institutions, enhancing its market presence and access to resources.
Weaknesses
1. Reliance on key customers: Guardant Health Inc may face risks due to its dependence on a few key customers for a significant portion of its revenue, making its financial performance vulnerable to changes in customer demand or preferences.
2. High research and development costs: Developing and improving liquid biopsy technology requires significant investment in research and development, which might strain the company's financial resources.
3. Regulatory challenges: As a healthcare company dealing with genetic testing and diagnostic tools, Guardant Health Inc is subject to stringent regulations, which may delay product approvals or limit market expansion.
Opportunities
1. Growing demand for precision medicine: With the increasing emphasis on personalized treatment approaches, Guardant Health Inc is well-positioned to benefit from the rising demand for precision medicine and targeted therapies.
2. Expansion into international markets: Guardant Health Inc can explore opportunities to expand its presence in international markets, where there is an increasing need for advanced genetic testing and improved cancer diagnostics.
3. Potential for partnerships with insurance providers: Collaborating with insurance providers to incorporate genetic testing as part of routine healthcare coverage could expand the customer base for Guardant Health Inc.
Threats
1. Competitive landscape: The market for liquid biopsy and genetic testing is highly competitive, with the presence of established players as well as emerging startups. Guardant Health Inc may face intense competition, which could impact market share and pricing.
2. Legal and ethical concerns: The use of genetic testing can raise privacy and ethical concerns. Guardant Health Inc needs to effectively address these issues to avoid potential legal challenges and maintain customer trust.
3. Economic downturn and healthcare industry changes: Guardant Health Inc's financial performance can be influenced by economic downturns and fluctuations in the healthcare industry, which might affect funding and reimbursement policies.
Guardant Health Segments
Guardant Health Revenue by Segment (1/2)
3 Years
5 Years
10 Years
25 Years
Max
Details
Guardant Health Revenue by Segment (2/2)
Max
Details
Guardant Health Revenue by Region
3 Years
5 Years
Max
Details
Guardant Health Eulerpool Fair Value
Guardant Health historical P/E ratio, EBIT multiple, and P/S ratio
Guardant Health annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Guardant Health shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Guardant Health Earnings Estimates
Guardant Health Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/7/2026 | -0.79USD | 287.58 MUSD | 2026 Q1 |
| 4/30/2026 | -0.79USD | 287.58 MUSD | 2026 Q1 |
| 4/28/2026 | -0.78USD | 288.12 MUSD | 2026 Q1 |
| 2/19/2026 | -0.72USD | 278.63 MUSD | 2025 Q4 |
| 5/7/2024 | -0.89USD | 155.79 MUSD | 2024 Q1 |
| 2/21/2024 | -0.89USD | 150.78 MUSD | 2023 Q4 |
| 8/2/2023 | -1.36USD | 141.15 MUSD | 2023 Q2 |
| 5/3/2023 | -1.39USD | 129.41 MUSD | 2023 Q1 |
| 2/21/2023 | -1.45USD | 126.02 MUSD | 2022 Q4 |
| 11/3/2022 | -1.3USD | 119.58 MUSD | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Guardant Health stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Guardant Health shareholder structure
| % | Name |
|---|---|
9.42472% | |
6.51377% | |
3.97989% | |
3.86251% | |
3.29867% | |
3.28812% | |
2.6847% | |
2.64221% | |
2.46757% | |
2.28078% |
Guardant Health Executives and Management Board
Dr. Amirali Talasaz
(45)Co-Chief Executive Officer, Director
Dr. Helmy Eltoukhy
(46)Chairperson of the Board, Co-Chief Executive Officer · since 2013
Ms. Terilyn Monroe
(58)Chief People Officer
Mr. Michael Bell
(56)Chief Financial Officer
Mr. Christopher Freeman
(51)Chief Commercial Officer
Frequently asked questions about Guardant Health
The main competitors of Guardant Health Inc in the market include companies such as Foundation Medicine, Exact Sciences Corporation, and Illumina Inc.
Guardant Health stock
Guardant Health Peer Group
Guardant Health Ticker
Guardant Health FIGI
All fundamentals and in-depth analysis of Guardant Health
Our stock analysis for Guardant Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guardant Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.